ATE239501T1 - Regulierung der neutrophil elastase synthese und freisetzung - Google Patents

Regulierung der neutrophil elastase synthese und freisetzung

Info

Publication number
ATE239501T1
ATE239501T1 AT96919130T AT96919130T ATE239501T1 AT E239501 T1 ATE239501 T1 AT E239501T1 AT 96919130 T AT96919130 T AT 96919130T AT 96919130 T AT96919130 T AT 96919130T AT E239501 T1 ATE239501 T1 AT E239501T1
Authority
AT
Austria
Prior art keywords
release
neutrophil elastase
regulation
tfpi
treatment
Prior art date
Application number
AT96919130T
Other languages
English (en)
Inventor
Kirk Johnson
Alba A Creasey
Lucien A Aarden
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,384 external-priority patent/US5885781A/en
Priority claimed from US08/483,459 external-priority patent/US6242414B1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE239501T1 publication Critical patent/ATE239501T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96919130T 1995-06-07 1996-06-05 Regulierung der neutrophil elastase synthese und freisetzung ATE239501T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/486,384 US5885781A (en) 1995-06-07 1995-06-07 Regulation of cytokine synthesis and release
US08/483,459 US6242414B1 (en) 1995-06-07 1995-06-07 Regulation of cytokine synthesis and release
PCT/US1996/009154 WO1996040224A1 (en) 1995-06-07 1996-06-05 Regulation of cytokine synthesis and release

Publications (1)

Publication Number Publication Date
ATE239501T1 true ATE239501T1 (de) 2003-05-15

Family

ID=27047651

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919130T ATE239501T1 (de) 1995-06-07 1996-06-05 Regulierung der neutrophil elastase synthese und freisetzung

Country Status (7)

Country Link
EP (1) EP0831893B1 (de)
JP (2) JPH11507060A (de)
AT (1) ATE239501T1 (de)
AU (1) AU708394B2 (de)
CA (1) CA2221601A1 (de)
DE (1) DE69628008T2 (de)
WO (1) WO1996040224A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
CA2446079A1 (en) * 2001-05-02 2002-11-07 Center For Blood Research, Inc. Modulators of elastase inhibitor secretion
SI1599222T1 (sl) * 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
JP2008500942A (ja) * 2003-01-08 2008-01-17 カイロン コーポレイション 組織因子経路インヒビターまたは組織因子経路インヒビター改変体を含有する安定化凍結乾燥組成物
JP4522997B2 (ja) 2003-08-13 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｔｆｐｉおよびｔｆｐｉアナログを精製するための改良された方法
CN101056989A (zh) 2004-11-08 2007-10-17 株式会社三菱化学药得论 血小板血栓或脏器损伤的检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
EP0643585B1 (de) * 1992-06-01 1999-12-15 Chiron Corporation Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
PT1489097E (pt) * 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury

Also Published As

Publication number Publication date
EP0831893B1 (de) 2003-05-07
JPH11507060A (ja) 1999-06-22
WO1996040224A1 (en) 1996-12-19
EP0831893A1 (de) 1998-04-01
DE69628008T2 (de) 2003-11-27
DE69628008D1 (de) 2003-06-18
AU6154896A (en) 1996-12-30
JP2007145870A (ja) 2007-06-14
AU708394B2 (en) 1999-08-05
CA2221601A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
BG107537A (en) Method for the inhibition of human tnf alpha activity and its application
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
BR9811260A (pt) Pequenas moléculas úteis no tratamento de doença inflamatória
NO20073429L (no) Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat
DE69526120T2 (de) Verwendung von nebivolol als anti-atherogenisches mittel
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
ATE251888T1 (de) Rosaceae extrakt als bradykinin-antagonist
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE239501T1 (de) Regulierung der neutrophil elastase synthese und freisetzung
HUP9802423A2 (hu) Hiperproliferatív megbetegedések kombinált gyógyászati kezelése
NO20000771L (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
NO980296D0 (no) Forbedrede terapeutiske midler
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
FR2734724B1 (fr) Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'alcoolisme
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
DK0703781T3 (da) Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom
FR2707166B1 (fr) Utilisation de l'efaroxan et de ses dérivés pour la fabrication de médicaments destinés au traitement de maladies neurodégénératives et leur progression .
KR940011006A (ko) 황금추출물을 유효성분으로 하는 치주질환예방 및 치료제 조성물
FR2657005B1 (fr) Systeme d'enclouage pour le traitement des fractures notamment du type cervico-trochanteriennes et pertrochanteriennes.
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
SE8202433L (sv) Linkomycin-3-(5'-ribonukleotider)lempade for behandling av protosoriska sjukdomar
TH23121A (th) การประยุกต์แบบใหม่ของไลโซไซม์ ไคเมอร์

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties